SHENZHEN, China, Oct. 20, 2025 /PRNewswire/ — From October 15 to 19, 2025, SKYWORTH showcased its all-new Matte Screen Ultra TV series, alongside a selection of standout TV products, at the 138th China Import and Export Fair (Canton Fair), highlighting its innovation and brand strength to visitors from around the world. As a long-standing exhibitor, SKYWORTH continues to uphold its core philosophy of “product first, continuous innovation,” committed to delivering better experiences for users globally.

Founded in 1988, SKYWORTH has grown into a global technology leader with operations spanning over 40 countries and regions, consistently ranked among the world’s top five TV brands by shipment volume. SKYWORTH is dedicated to innovation in television display technologies, continuously improving user experiences and driving industry advancement, with extensive expertise in OLED, QLED, and Mini LED technologies. Its strong product performance and brand influence have earned growing recognition in international markets, establishing SKYWORTH as a regular highlight at the Canton Fair.

At the 138th Canton Fair, SKYWORTH unveiled its latest Matte Screen Ultra QD-Mini LED TV series, marking a major leap in next-generation display technology. Featuring multiple layers of high-performance materials, the new screen achieves exceptional contrast, ultra-wide viewing angles, and brilliant brightness, while its anti-glare design enhances visual comfort. The result is OLED-level performance, with deeper blacks, sharper contrast, and crystal-clear, glare-free images even in bright environments. Viewers can enjoy vivid and accurate colors from any position —sitting, lying down, or moving across the room—bringing a truly immersive experience to everyday viewing. Together, these innovations redefine what premium home entertainment looks and feels like.

Beyond cutting-edge technology, SKYWORTH showcased its rich and diverse product portfolio. Highlights included the 100-inch Frame+ TV, one of the largest models in its class, which doubles as a wall-mounted art piece, blending interior aesthetics with entertainment. Also on display were SKYWORTH’s globally best-selling 100-inch TVs, high-performance gaming TVs with superior sound, the world’s first AI Karaoke Google TV, and a range of portable TVs. This dynamic mix of products and smart interactive experiences created an engaging and inspiring showcase for all visitors.

The 138th Canton Fair once again demonstrated SKYWORTH’s unwavering commitment to innovation, quality, and user experience, impressing visitors from around the world. To explore SKYWORTH’s full range of breakthrough products and cutting-edge technologies, visit: https://overseas.skyworth.com/en/home.

UDAIPUR, India, Oct. 20, 2025 /PRNewswire/ — India based Hindustan Zinc Limited, a Vedanta Group company and the world’s largest integrated zinc producer, announced its financial results on 17^th October 2025 for the second quarter and half year ended 30^th September 2025.The company reported its best-ever second quarter mined metal production of 258 Kt, alongside five-year lowest zinc cost of production excluding royalty at $ 994 per tonne. The company also recorded its highest-ever 2Q revenue from operations of US$ 979 million, up 10% QoQ and 4% YoY, and best-ever second-quarter EBITDA of US$ 512 million, up 16% QoQ and 7% YoY, maintaining industry-leading EBITDA margin of 52%. Resultantly, profit after tax stood at US$ 303 million, rising 19% QoQ and 14% YoY.

Hindustan Zinc employees with ingots

Silver remained a strong contributor, driving approximately 40% of overall profitability. During the quarter, Hindustan Zinc also delivered superior total shareholder returns of 7%, underscoring its consistent value creation. Reflecting strong market performance and investor confidence, the company was included in Nifty 100 and Nifty Next 50 indices, effective September 30, 2025. The Board approved India’s first 10 Mtpa Zinc Tailings Reprocessing Plant, a milestone in advancing resource circularity and sustainable growth.

Commenting on Hindustan Zinc’s performance, Arun Misra, Chief Executive Officer, said:

“I am delighted to share that we have delivered the best-ever second quarter mined metal production with a 5-year lowest zinc cost of production of $994 per tonne, reflecting the continuous operational excellence, technology intervention and dedication of our people. Our inclusion into the International Council on Mining and Metals (ICMM) as the first-ever from India reiterates our deep commitment to responsible and sustainable mining. As we embark on our next phase of 2x growth expansion, recovering value from every resource, reusing materials through circular processes and growing portfolio of energy transition metals, we are driving India’s journey towards clean energy independence.”

_{USD-INR rate is 87.31}

About Hindustan Zinc Limited:

Hindustan Zinc Limited, a Vedanta Group company, is the world’s largest integrated zinc producer. The company has been recognized as the world’s most sustainable metals & mining company by the S&P Global CSA 2024 and the first Indian company to become an ICMM member.

Media Contact:
Maitreyee Sankhla (Head Corporate Communications)
maitreyee.sankhla@vedanta.co.in 

Disclaimer

This release contains forward-looking statements that may differ from actual results. We undertake no obligation to update them.

SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced that the latest results from the ongoing Phase I/II CLINCH study of ATG-022 (CLDN18.2 antibody-drug conjugate [ADC]), were presented in a Poster Presentation at the European Society for Medical Oncology Congress 2025 (ESMO 2025) in Berlin, Germany.

Details of the Poster Presentation:
ATG-022 (CLDN18.2 antibody-drug conjugate)
Title: Phase I/II study of Claudin 18.2 ADC ATG-022 in patients with advanced gastric/ gastroesophageal junction cancer (CLINCH)
Abstract Number: 2907
Presentation Number: 2113P

ATG-022 and CLINCH Study Overview

• ATG-022 is a CLDN18.2-targeted ADC with sub-nM affinity and fast internalization. Using a VC-MMAE linker-payload (DAR 4), ATG-022 has demonstrated potent activity across tumors with high, low, and ultra-low CLDN18.2 expression.
• The ongoing Phase I/II CLINCH study consists of dose escalation and dose expansion phases. In dose escalation, patients with advanced solid tumors regardless of CLDN18.2 expression receive ATG-022 once every three weeks (0.3-3.0 mg/kg Q3W) to evaluate the safety, tolerability, and pharmacokinetics; CLDN18.2-positive (≥ IHC 1+, 1%) patients are treated at 1.8 mg/kg or 2.4 mg/kg in dose expansion to evaluate the efficacy and safety.
• ATG-022 has been granted two Orphan Drug designations (ODDs) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer, and in August 2025 obtained Breakthrough Therapy Designation from China’s National Medical Products Administration (NMPA) for treating CLDN18.2-positive, HER-2 negative unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have received at least two prior lines of therapy.

Key Results from the CLINCH Study

• Efficacy Data
  • Among GC/GEJC patients with moderate/high CLDN18.2 expression (IHC 2+ > 20%), the 2.4 mg/kg dose cohort observed 1 complete response (CR), 11 partial responses (PRs) and 15 stable diseases (SDs), resulting in an objective response rate (ORR) of 40% (12/30) and a disease control rate (DCR) of 90% (27/30). The median progression-free survival (mPFS) was 6.97 months and the 12-month overall survival (OS) rate was 66.2%. In the 1.8 mg/kg dose cohort, there were 1 CR, 9 PRs, and 11 SDs, resulting in an ORR of 40% (10/25) and a DCR of 84% (21/25).
  • Among GC/GEJC patients with low/ultra low CLDN18.2 expression (IHC 2+ ≤ 20%), patients treated at the efficacious dose of 1.8-2.4 mg/kg achieved 1 CR and 5 PRs, resulting in an ORR of 33.3% (6/18) and a DCR of 50% (9/18). The patient with CR has demonstrated durable response and has been on the study for over 22 months.
  • To date, the study has observed three CRs, one from each of the three forementioned cohorts (two dose cohorts among CLDN18.2 mid/high expressors and the cohort of low/ultra low CLDN18.2 expressors). This broad-spectrum antitumor activity indicates ATG-022’s potential as a new treatment option for a broader population of patients).
• Safety Data
  • At 2.4 mg/kg in the dose expansion, 45.8% of patients had ≥1 treatment-emergent adverse events (TEAEs), 60.4% of patients had grade ≥3 TEAEs. The most common grade ≥3 treatment-related adverse events (TRAEs, ≥5% of patients) were neutrophil count decrease (16.7%), decreased appetite (14.6%) and anaemia (8.3%).
  • In the dose-expansion phase, the 1.8 mg/kg cohort demonstrated excellent safety and tolerability, with only 13.6% of patients reporting serious TEAEs and 18.2% reporting Grade ≥3 TEAEs. The favorable safety profile of this dose level support its potential use in first-line combination regimens with chemotherapy and immune checkpoint inhibitors.
  • No ophthalmological toxicities or interstitial lung disease have been observed.

Conclusions and Outlook

• ATG-022 demonstrated a manageable safety profile and encouraging antitumor effects in GC/GEJC adenocarcinoma patients with a broad range of CLDN18.2 expressions, thus supporting further clinical investigation in patients with variable CLDN18.2 expressions. In addition to GC/GEJC, preliminary efficacy has been observed in other non-GI tumor types which will be reported at upcoming conferences.
• The 2.4 mg/kg cohort showed a favorable safety profile, while the 1.8 mg/kg cohort demonstrated even better safety and tolerability. These findings provide strong support for advancing ATG-022 in combination with immune checkpoint inhibitors and chemotherapy in first-line treatment settings, paving the way to significantly expand its clinical reach and commercial potential.
• The Phase II dose expansion study of ATG-022 is going smoothly in China and Australia. In parallel, Antengene is actively preparing for combination therapy studies involving ATG-022 to further advance its clinical development.

About Antengene

Antengene Corporation Limited (“Antengene“, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 × 4-1BB bispecific antibody), ATG-031 (CD24-targeting macrophage activator), and ATG-042 (oral PRMT5-MTA inhibitor).

Antengene has also developed AnTenGager™, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low-expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies indications.

To date, Antengene has obtained 31 investigational new drug (IND) approvals in the U.S. and Asia, and submitted new drug applications (NDAs) in 11 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2024, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: Donald.Lung@antengene.com
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: Peter.Qian@antengene.com
Mobile: +86 13062747000

Promo Code FLYOCT & Special Coupons for Travel through March 2026

TAIPEI, Oct. 20, 2025 /PRNewswire/ — T’way Air, Korea’s leading low-cost carrier, invites travelers to enjoy special savings through October 31 on Taiwan-Korea bookings for travel until March 28, 2026.

T’way Air currently operates seven direct flights to Korea: Songshan–Gimpo (Seoul), Taipei–Jeju, Taipei–Daegu, Taichung–Incheon (Seoul), Kaohsiung–Gimpo (Seoul), Kaohsiung–Incheon (Seoul), and Kaohsiung–Jeju. Full route maps and flight schedules are available at twayair.com.

T’way Air is offering the following offers until October 31:

• Up to 15% Off Promo Code: enter promo code FLYOCT when booking, for travel through March 28, 2026. (actual savings may vary with the exchange rate at purchase).
• First-Come TWD 500 Off Coupon: bookings of TWD 5,000 or more, travel through March 28, 2026; valid on Taipei–Jeju, and Kaohsiung–Jeju
• TWD 300 Off Coupon: bookings of TWD 3,000 or more, travel through March 28, 2026.
• TWD 800 Off Coupon: bookings of TWD 7,000 or more, travel through March 28, 2026.
• TWD 400 Early Bird Coupon: bookings of TWD 3,000 or more, travel period December 1 – March 28, 2026.
• TWD 900 Early Bird Coupon: bookings of TWD 7,000 or more, travel period December 1 – March 28, 2026.

Start in Myeongdong for street food and nonstop shopping. Walk the fortress wall in Naksan Park for sunset views, and look over the Seoul skyline from N Seoul Tower. Then try local favorites – gimbap, naengmyeon, seollongtang, and Korean hot dog – all close to major shopping and cultural hotspots. With T’way Air flights to Korea, planning a culture-rich trip is easy, and the Korean Wave adds to the fun. For a change of pace, head to Jeju Island for coastal trails and a relaxed vibe beloved by locals.

For full flight schedules, coupon terms, and booking details, visit twayair.com. T’way Air currently serves 60 destinations worldwide and continues to expand its network.

About T’way Air

T’way Air Co., Ltd., headquartered in Daegu, South Korea, is a leading low-cost carrier (LCC) providing affordable and reliable air travel since 2010. T’way Air serves customers across East Asia, Southeast Asia, Central Asia, Oceania, and Europe with a modern fleet of Boeing 737-800s, 737 MAX 8s, and Airbus A330-300, A330-200, and Boeing 777-300ERs. T’way Air continues to expand its global network, offering great value to passengers worldwide. For more information, please visit www.twayair.com.

Media Contact

T’WAY AIR Public Relations

twaypr@twayair.com